WO2008009856A3 - Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée - Google Patents

Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée Download PDF

Info

Publication number
WO2008009856A3
WO2008009856A3 PCT/FR2007/051683 FR2007051683W WO2008009856A3 WO 2008009856 A3 WO2008009856 A3 WO 2008009856A3 FR 2007051683 W FR2007051683 W FR 2007051683W WO 2008009856 A3 WO2008009856 A3 WO 2008009856A3
Authority
WO
WIPO (PCT)
Prior art keywords
acne
treatment
hyperseborrhoea
modulators
hsd17b7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/051683
Other languages
English (en)
Other versions
WO2008009856A2 (fr
Inventor
Fernand Labrie
Van Luu-The
Ezequiel L Calvo
Jerome Aubert
Michel Rivier
Sophie Deret
Johannes Voegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to CA002656841A priority Critical patent/CA2656841A1/fr
Priority to EP07823602A priority patent/EP2046975A2/fr
Publication of WO2008009856A2 publication Critical patent/WO2008009856A2/fr
Publication of WO2008009856A3 publication Critical patent/WO2008009856A3/fr
Anticipated expiration legal-status Critical
Priority to US12/320,169 priority patent/US20100028879A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité de l'hydroxystéroïde (17-beta) deshydrogénase de type 7, ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de cette enzyme pour le traitement de l'acné ou des désordres cutanés associés à une hyperséborrhée. L'invention concerne aussi des méthodes de diagnostic in vitro ou pronostic in vitro de ces pathologies.
PCT/FR2007/051683 2006-07-19 2007-07-18 Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée Ceased WO2008009856A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002656841A CA2656841A1 (fr) 2006-07-19 2007-07-18 Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
EP07823602A EP2046975A2 (fr) 2006-07-19 2007-07-18 Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée
US12/320,169 US20100028879A1 (en) 2006-07-19 2009-01-21 Modulators of HSD17b7 for treating acne or hyperseborrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653029A FR2904000A1 (fr) 2006-07-19 2006-07-19 Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
FR0653029 2006-07-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/320,169 Continuation US20100028879A1 (en) 2006-07-19 2009-01-21 Modulators of HSD17b7 for treating acne or hyperseborrhea

Publications (2)

Publication Number Publication Date
WO2008009856A2 WO2008009856A2 (fr) 2008-01-24
WO2008009856A3 true WO2008009856A3 (fr) 2008-03-06

Family

ID=37708241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051683 Ceased WO2008009856A2 (fr) 2006-07-19 2007-07-18 Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée

Country Status (5)

Country Link
US (1) US20100028879A1 (fr)
EP (1) EP2046975A2 (fr)
CA (1) CA2656841A1 (fr)
FR (1) FR2904000A1 (fr)
WO (1) WO2008009856A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938335A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de l'isovaleryl-coenzyme a dehydrogenase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2018136702A1 (fr) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Variants de la 17-bêta-hydroxystéroïde déshydrogénase 13 (hsd17b13) et leurs utilisations
EP3610029A1 (fr) * 2017-04-11 2020-02-19 Regeneron Pharmaceuticals, Inc. Dosage de criblage de l'activité des modulateurs de membres de la famille des hydroxystéroïde (17-bêta) déshydrogénase (hsd17b)
CN111183234A (zh) 2017-10-11 2020-05-19 雷杰纳荣制药公司 在表达pnpla3 i148m变异的患者的肝病治疗中对hsd17b13的抑制
BR112020018758A2 (pt) 2018-03-21 2021-01-26 Regeneron Pharmaceuticals, Inc. agente de ácido ribonucleico de fita dupla, célula, vetor, composição farmacêutica, e, métodos para inibição da expressão de 17¿-hidroxiesteroide desidrogenases tipo 13, para tratamento de um indivíduo, para prevenção de um sintoma em um indivíduo, para redução do risco de desenvolver doença hepática crônica, para inibição da progressão de esteatose, para inibição do acúmulo de gotículas de lipídios
CN117264008A (zh) * 2022-06-15 2023-12-22 中国科学院大连化学物理研究所 一种化合物及应用和抑制剂与药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032527A2 (fr) * 2003-06-10 2005-04-14 Solvay Pharmaceuticals B.V. Nouveaux composés et leur utilisation en thérapie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030071B2 (en) * 2005-03-11 2011-10-04 Gargi Seth Restoration of cholesterol independence and its use as a selectable marker in NS0 cell culture

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032527A2 (fr) * 2003-06-10 2005-04-14 Solvay Pharmaceuticals B.V. Nouveaux composés et leur utilisation en thérapie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIU H. ET AL.: "Cloning and characterization of human form 2 type 7 17beta-hydroxysteroid dehydrogenase, a primarily 3beta-keto reductase and estrogen activating and androgen inactivating enzyme", J. STEROID BIOCHEM. MOL. BIOL., vol. 94, no. 1-3, February 2005 (2005-02-01), pages 173 - 179, XP004874312, ISSN: 0960-0760 *
LUU-THE V.: "Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase.", J. STEROID BIOCHEM. MOL. BIOL., vol. 76, no. 1-5, January 2001 (2001-01-01), pages 143 - 151, XP002419837 *
OHNESORG T. ET AL.: "Analysis of the 5' flanking regions of human and murine HSD17B7: Identification of a cholesterol dependent enhancer region.", MOL. CELL. ENDOCRINOL., vol. 248, no. 1-2, 27 March 2006 (2006-03-27), pages 164 - 167, XP005335816, ISSN: 0303-7207 *
POIRIER D.: "Inhibitors of 17beta-hydroxysteroid dehydrogenases.", CURR. MED. CHEM., vol. 10, 2003, pages 453 - 477, XP009024878, ISSN: 0929-8673 *

Also Published As

Publication number Publication date
US20100028879A1 (en) 2010-02-04
CA2656841A1 (fr) 2008-01-24
WO2008009856A2 (fr) 2008-01-24
FR2904000A1 (fr) 2008-01-25
EP2046975A2 (fr) 2009-04-15

Similar Documents

Publication Publication Date Title
WO2008043087A3 (fr) Composés hétérocycliques azotés bicycliques pour une utilisation en tant qu'inhibiteurs de stéaroyl-coa-désaturase
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
WO2007127505A3 (fr) Composés chimiques
WO2007117344A3 (fr) systemes et procedes de differenciation et/ou d'identification de regionS tissulaires innervees par des nerfs cibles a des fins diagnostiques et/ou therapeutiques
WO2007137071A3 (fr) Compositions de r(+) et s(-) pramipéxole et procédés d'utilisation de celles-ci
WO2008009856A3 (fr) Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée
WO2009124330A3 (fr) Traitement de maladies tumorales
WO2007053622A3 (fr) Méthodes pour moduler une activité biologique ppar pour le traitement de maladies causées par des mutations du gène cftr
WO2010039536A3 (fr) Sirt4 et utilisations de celui-ci
TW200745047A (en) Heterocyclic compounds
WO2008009855A3 (fr) Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
WO2009066299A3 (fr) Utilisation du génotypage de l'haptoglobine dans le diagnostic et le traitement d'une maladie cardiovasculaire
WO2007101063A3 (fr) Traitement de troubles liés au développement
WO2008009859A3 (fr) Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009857A3 (fr) Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation
WO2008009854A3 (fr) Modulateurs du transporteur abcd3 dans le traitement de l'acné ou de l'hyperséborrhée
WO2009017719A8 (fr) Modulateurs du récepteur ccr9 et leurs procédés d'utilisation
WO2008070552A3 (fr) Inhibiteurs de la protéine tyrosine phosphatase permettant de favoriser l'hypertrophie cardiaque physiologique
WO2008009858A3 (fr) Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
WO2007038264A3 (fr) Methodes associees a gapr-1
WO2008009852A3 (fr) Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée
WO2006019978A3 (fr) Compositions et procedes pour le diagnostic et le traitement d'epilepsie
WO2008057313A3 (fr) Procédés d'utilisation de e2f2 pour le traitement de l'hypertension
WO2009004247A3 (fr) Inhibiteurs de tace dans le traitement de l'acne
WO2006009950A3 (fr) Genes aldo utilises comme modificateurs de la voie igf et procedes d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823602

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007823602

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2656841

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU